Ignite Creation Date:
2025-12-24 @ 4:12 PM
Ignite Modification Date:
2026-01-06 @ 5:34 AM
Study NCT ID:
NCT05162066
Status:
TERMINATED
Last Update Posted:
2024-05-02
First Post:
2021-11-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Sponsor:
BioCryst Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-18
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-23
Completion Date Type:
ACTUAL
First Submit Date:
2021-11-26
First Submit QC Date:
None
Study First Post Date:
2021-12-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-04-08
Results First Submit QC Date:
None
Results First Post Date:
2024-05-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-08
Last Update Post Date:
2024-05-02
Last Update Post Date Type:
ACTUAL